Adaptimmune Therapeutics(us:ADAP)
0.2500
+26.90%
Updated on 2025-04-02
Open:0.1951
Close:0.2500
High:0.2535
Low:0.1951
Prev Close:0.1970
Volume:5.91M
Turnover:1.30M
Turnover Ratio:2.30%
Shares:257.23M
MarketCap:64.31M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 1 | 0 | 0 | 0 | 1 | |
| 2024-03-31 | 94 | 162089971 | 63.44% | 17 | 17 | 37 |
| 2023-12-31 | 92 | 143626744 | 63.22% | 15 | 14 | 41 |
| 2023-09-30 | 95 | 148305169 | 65.35% | 7 | 16 | 41 |
| 2023-06-30 | 106 | 144694354 | 64.22% | 9 | 21 | 54 |
| 2023-03-31 | 111 | 147633436 | 89.14% | 7 | 26 | 42 |
| 2022-12-31 | 79 | 113873931 | 69.22% | 12 | 16 | 36 |
| 2022-09-30 | 85 | 113867889 | 69.52% | 10 | 20 | 32 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Matrix Capital Management Company, Lp | 38974185 | 15.25% | 0 | |
| 2024-03-31 | Ecor1 Capital, Llc | 27404070 | 10.73% | 27404070 | |
| 2024-03-31 | Nea Management Company, Llc | 17079778 | 6.68% | 0 | |
| 2024-03-31 | Baillie Gifford & Co | 15871875 | 6.21% | -40265 | -0.25% |
| 2024-03-31 | Baker Bros. Advisors Lp | 10787022 | 4.22% | -182260 | -1.66% |
| 2024-03-31 | Long Focus Capital Management, Llc | 10684233 | 4.18% | -1402682 | -11.61% |
| 2024-03-31 | Pfm Health Sciences, Lp | 10423135 | 4.08% | 0 | |
| 2024-03-31 | Mpm Asset Management Llc | 5555461 | 2.17% | 0 | |
| 2024-03-31 | Mpm Bioimpact Llc | 5095912 | 1.99% | 0 | |
| 2024-03-31 | Bank Of America Corp /De/ | 4667787 | 1.83% | -30167 | -0.64% |
About
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Address:60 Jubilee Avenue,Milton Park
Website:http://www.adaptimmune.com
Market Movers